VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 24.4% in January

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 8,396 shares, a decrease of 24.4% from the December 31st total of 11,105 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 42,227 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 42,227 shares, the short-interest ratio is currently 0.2 days. Approximately 0.3% of the company’s stock are sold short.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. Hedge funds and other institutional investors own 8.23% of the company’s stock.

VivoSim Labs Stock Down 16.8%

Shares of VIVS opened at $2.43 on Tuesday. The stock has a market cap of $6.34 million, a P/E ratio of -0.55 and a beta of 1.21. The business’s 50 day moving average price is $2.07 and its 200-day moving average price is $2.36. VivoSim Labs has a 52 week low of $1.41 and a 52 week high of $21.96.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%. The company had revenue of $0.03 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, VivoSim Labs presently has an average rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.